Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Equity Ratio (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Equity Ratio readings, the most recent being 0.77 for Q4 2025.

  • On a quarterly basis, Equity Ratio changed 0.4% to 0.77 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.77, a 0.4% change, with the full-year FY2025 number at 0.77, changed 0.4% from a year prior.
  • Equity Ratio hit 0.77 in Q4 2025 for Sunshine Biopharma, roughly flat from 0.77 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 1.0 in Q2 2022 to a low of 0.58 in Q1 2021.
  • Median Equity Ratio over the past 5 years was 0.78 (2023), compared with a mean of 0.58.
  • Biggest five-year swings in Equity Ratio: soared 669.7% in 2022 and later decreased 27.5% in 2023.
  • Sunshine Biopharma's Equity Ratio stood at 0.1 in 2021, then soared by 669.7% to 0.74 in 2022, then increased by 4.86% to 0.78 in 2023, then decreased by 0.84% to 0.77 in 2024, then decreased by 0.4% to 0.77 in 2025.
  • The last three reported values for Equity Ratio were 0.77 (Q4 2025), 0.77 (Q3 2025), and 0.8 (Q2 2025) per Business Quant data.